MAP2K7 and post-traumatic stress disorder: The critical contribution of the present study is to show for the first time, the evidence for clinical translatable MEK inhibitor to disrupt weak as well as strong fear memories and further development of practical strategy for destabilization of strong fear memories that can be used in future clinical development of mirdametinib for PTSD.